🔗 Share this article

Given that the United States continues making unprecedented changes to its immunization guidelines, one figure has emerged in a surprising turn: Tracy Beth Høeg, a Danish American physician and public health researcher who initially gained attention by casting doubt on COVID-19 vaccinations in the pandemic and has zeroed in on potential fatalities following Covid immunization in her brief position at the Food and Drug Administration.

Proposed Changes to Childhood Vaccine Schedule

Agency leaders were set to announce sweeping revisions to the pediatric vaccination calendar recently, bringing the US with the Danish national calendar, sources say – a significant shift that would place the US out of alignment with many the international standard with insufficient data for benefit. The planned update has been delayed until the new year.

Rather than the top vaccines chief, Høeg is listed to speak at the event. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the center this calendar year.

A New Direction at the Regulatory Body

The acting appointment could signify a strengthened alliance between the pharmaceutical and vaccine divisions as Høeg and Prasad consolidate power at the FDA – and it suggests a greater focus upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for ending some childhood immunization guidelines in the US to become more like the Danish model, a society with universal health coverage and a population approximately the population of Wisconsin’s.

In her initial comments, she has continued to focus on vaccination policy – typically the domain of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Concerns Over Qualifications

The appointee has no apparent background in medication creation, oversight or administrative roles, which has been typical for former directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the agency head and the vaccine center since March.

“She doesn’t seem to have any of the qualifications” for overseeing the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She’s never run a scientific study. She has no expertise in leading a large organization. She has no expertise in industry regulation.”

Previous directors of the center would “be deeply familiar with legal statutes and the underlying principles of drug development”, said Janet Woodcock. “Clearly, she has not acquired the kind of background that former directors who led CBER have had.”

This division has an enormous range of responsibilities at the FDA, she pointed out.

“Everybody just zeroes in on the new drug program, but the generic drug division clears thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, OTC medication office and so forth, and all of those need to be managed,” she explained. “The area you neglect, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a significant leadership aspect to the job, which supervises more than 5,000 staff members. “It is a enormous leadership role, if you do it right,” the former official said.

Response and Disputed Policies

When asked about questions about Dr. Høeg's qualifications and whether this appointment represents more teamwork among regulatory chiefs on vaccines, a representative stated that the “concerns are based on flawed presumptions”.

“Her resume aligns with the functions of her position,” the official explained, citing the time Dr. Høeg spent guiding the FDA commissioner on “drug safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As acting director, Høeg takes over the agency head's recently launched priority voucher program, a contentious one-day therapy clearance system that apparently worried her predecessors. “By what process are these drugs being picked for this expedited pathway? Who makes the choices?” Dr. Howard said. “There’s a lot of confidentiality happening at the regulatory body right now.”

In general, he stated, “the FDA seems to be moving towards laxer rules of pharmaceuticals, except for vaccines.”

Documented Past Work on Immunizations

With vaccines, Høeg has a more established, if problematic, history, Howard have noted. She released a research paper using unconfirmed public submissions to determine the rate of heart inflammation after COVID-19 vaccination. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to indicate Covid vaccinations are more dangerous than they are.

Included in her “desired changes” for the new federal leadership encompassed changing rules for novel immunizations and halting “non-essential” immunizations, she stated after the election on a podcast. At the FDA, Dr. Høeg has according to sources suggested preventing young men from receiving COVID-19 vaccinations.

“She’s an complete true believer who starts off with her beliefs and tailors the evidence to retrofit the science in a extremely misleading, fraudulent fashion,” Dr. Howard stated.

Consolidating Power and a “Revenge Tour”

Høeg aligned with other dissenters, {like|